42 completed, 10 recruiting, 4 terminated, 4 unknown. 28 Phase 2, 23 Phase 3, 7 Phase 4, 5 Not applicable, 5 Phase 1.
Follow 4-Aminopyridine: new trials by email Literature Review of 4-Aminopyridine trials Research Report on 4-Aminopyridine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Influence of Fampridine on Working Memory in Healthy Subjects Fampridine SR, Placebo - Working Memory | Phase 2 | Withdrawn | Prof. Dominique de Quervain, MD | 2040-01-01 | 2024-12-05 | |
| Single Dose 4-Aminopyridine for Diagnosing Recurrent Laryngeal Nerve Paralysis Continuity After Trauma 4-Aminopyridine - Vocal Cord Paralysis, Recurrent Laryngeal Nerve Palsy | Phase 1 | Not yet recruiting | Milton S. Hershey Medical Center | 50 | 2026-12-01 | 2026-09-21 |
| 4AP for Carpal Tunnel Syndrome (CTS) 4-Aminopyridine, Placebo - Compression Neuropathy, Carpal Tunnel Syndrome | Phase 2 | Not yet recruiting | John Elfar | 160 | 2026-11-01 | 2026-01-26 |
| The Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users 4-aminopyridine (4-AP), Placebo - Cocaine Use Disorder (CUD), Cognitive Impairments | Not applicable | Recruiting | Boris Quednow | 40 | 2026-05-28 | 2026-08-17 |
| Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor Imatinib, Fampridine - Gastrointestinal Stromal Tumors | Phase 1 | Recruiting | University of California, San Diego | 18 | 2026-05-13 | 2026-05-27 |
| 4-Aminopyridine to Treat Skin Burns Drug: 4-Aminopyridine, Placebo - Burns, Second Degree Burn | Phase 2 | Recruiting | John Elfar | 200 | 2026-01-01 | 2026-03-05 |
| A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene Fampridine 10 mg prolonged-release tablet (per os), Placebo (tablets per os) - Spinocerebellar Ataxia 27B (SCA27B) | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 70 | 2025-10-21 | 2025-12-10 |
| 4-aminopyridine for Skin Wound Healing 4-Aminopyridine, Placebo - Wounds, Wound of Skin | Phase 2 | Recruiting | John Elfar | 150 | 2025-09-01 | 2025-09-03 |
| Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression Fampridine SR, Placebo - Working Memory, Mild to Moderate Depression | Phase 2 | Recruiting | University of Basel | 38 | 2025-05-22 | 2026-10-20 |
| 4-AP Peripheral Nerve Crossover Trial 4-Aminopyridine, Placebo - Peripheral Nerve Injury, Crush Injury | Phase 2 | Recruiting | University of Arizona | 68 | 2025-04-21 | 2025-08-05 |
| Double Dose 4-AP on Functional Recovery After Spinal Cord Injury Dalfampridine, Placebo, STDP stimulation - SCI - Spinal Cord Injury | Phase 1 / Phase 2 | Recruiting | Shirley Ryan AbilityLab | 27 | 2025-02-01 | 2026-06-03 |
| Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis Dalfampridine 10 MG [Ampyra], Physical therapy, Dalfampridine plus physical therapy - Multiple Sclerosis | Phase 3 | Recruiting | MGH Institute of Health Professions | 48 | 2024-06-12 | 2026-07-20 |
| Effects of 4-AP on Functional SCI Recovery Dalfampridine, Placebo drug, STDP stimulation - Spinal Cord Injury | Early Phase 1 | Completed | Shirley Ryan AbilityLab | 26 | 2022-06-30 | 2026-06-03 |
| Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive Impairment Fampridine SR, Placebo - Working Memory, Post-covid-19 | Not applicable | Terminated | Prof. Dominique de Quervain, MD | 8 | 2022-06-28 | 2024-07-18 |
| Fampridine-SR and Optic Neuritis Recovery Fampridine SR - Optic Neuritis | Early Phase 1 | Unknown | Courtney Casserly | 20 | 2022-03-22 | 2022-08-25 |
| Influence of Fampridine on Working Memory in Healthy Young Subjects Fampridine SR, Placebo - Working Memory | Phase 2 | Completed | Prof. Dominique de Quervain, MD | 44 | 2021-11-01 | 2023-02-06 |
| A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma 4-Aminopyridine, Placebo oral tablet - Nerve Injury | Phase 2 / Phase 3 | Terminated | Milton S. Hershey Medical Center | 1 | 2021-08-17 | 2022-10-18 |
| 4-aminopyridine Treatment for Nerve Injury 4-Aminopyridine, Placebo - Nerve Injury, Prostate Cancer | Phase 2 / Phase 3 | Recruiting | John Elfar | 70 | 2021-06-05 | 2025-12-17 |
| Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia Dalfampridine 10 MG, Placebo, Physiotherapy - Hereditary Spastic Paraplegia | Not applicable | Completed | European University of Lefke | 8 | 2020-08-03 | 2022-11-22 |
| High Doses of 4-aminopyridine in Clinically Complete Chronic Spinal Cord Injury Patients. 4-Aminopyridine, Placebo oral capsule - Spinal Cord Injuries, Chronic | Phase 3 | Unknown | Coordinación de Investigación en Salud, Mexico | 150 | 2019-07-17 | 2021-02-21 |
Showing 20 of 66. Sign in to see all of them.
Multiple Sclerosis (32) · Spinal Cord Injuries (6) · Demyelinating Diseases (4) · Fatigue (4) · Muscle Spasticity (3) · Multiple Sclerosis, Chronic Progressive (2) · Optic Neuritis (2) · Wounds and Injuries (2) · Ataxia (1) · Blast Injuries (1) · Bronchiolitis Obliterans Syndrome (1) · Burns (1) · Carpal Tunnel Syndrome (1) · Cognitive Dysfunction (1) · Crush Injuries (1)
Acorda Therapeutics (12) · Biogen (8) · John Elfar (4) · Prof. Dominique de Quervain, MD (3) · University of Southern Denmark (3) · Coordinación de Investigación en Salud, Mexico (2) · Milton S. Hershey Medical Center (2) · Shirley Ryan AbilityLab (2) · Assistance Publique - Hôpitaux de Paris (1) · Boris Quednow (1) · Brigham and Women's Hospital (1) · Centre Hospitalier Universitaire de Besancon (1) · Columbia University (1) · Courtney Casserly (1) · D'Youville College (1)
United States (37) · Canada (15) · Switzerland (6) · France (5) · Denmark (4) · Netherlands (4) · Italy (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Czechia (2) · Germany (2) · Ireland (2) · Israel (2) · Mexico (2)
John Elfar, MD (5) · Bonnie Faust (3) · Dominique de Quervain, Prof. MD (3) · Andreas Papassotiropoulos, Prof. MD (2) · Andrew Blight, PhD (2) · Gabriel Pardo, MD (2) · Henrik B Jensen, MD (2) · Holly Roberts, MD (2) · Aaron Boster, MD (1) · Adam DiDio, MD (1) · Alan Schulman, MD (1) · Alessandro Serra, MD PhD (1) · Anat Achiron, MD, PhD (1) · Andreas Papassotiropoulos, Prof (1)
PMID 20976768, PMID 12525714, PMID 14606742, PMID 15147583, PMID 16283615, PMID 16980142, PMID 17895294, PMID 17942508, PMID 18653737, PMID 18951800, PMID 19068404, PMID 19249634, PMID 1992392, PMID 20594850, PMID 21112438, PMID 22315143, PMID 23247892, PMID 23535489, PMID 23791482, PMID 23962697, PMID 24090757, PMID 24378281, PMID 24503204, PMID 24852920, PMID 25560174, PMID 25583832, PMID 26041616, PMID 26409700, PMID 26565077, PMID 26762672, PMID 26810506, PMID 26843986, PMID 27004639, PMID 27919481, PMID 28148629, PMID 28387543, PMID 30171655, PMID 30535670, PMID 30566030, PMID 30593980, PMID 32500374, PMID 32634812, PMID 32651338, PMID 33528792, PMID 34322853, PMID 35487034, PMID 36436320, PMID 37804674, PMID 38773595, PMID 39516710
1IK2RX001180-01A2 (1), 2025 (1), R01NS111293 (1), R35NS122336 (1)